PURPOSE OF REVIEW: To delineate how recent findings on prostate-specific antigen (PSA) can improve prediction of risk, detection, and prediction of clinical endpoints of prostate cancer (PCa). RECENT FINDINGS: The widely used PSA cut-point of 4.0 ng/ml increasingly appears arbitrary, but no cut-point achieves both high sensitivity and high specificity. The accuracy of detecting PCa can be increased by additional predictive factors and a combinations of markers. Evidence implies that a panel o...Expand abstract
- Publisher copy:
- Copyright date:
Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
If you are the owner of this record, you can report an update to it here: Report update to this record